GlucoTrack has no meaningful revenue yet and negative earnings, but possesses peer-reviewed data in serious journals backing its main technology. Recent publications in IEEE Sensors Journal confirm year-long sensor stability in-vitro, while Journal of Diabetes Research shows 240-day accuracy in a live ovine model. As of January 2026, the USPTO issued three patents for the company's glucose monitoring technology.
Cyborg Score Rationale
Early-stage biotech with promising preclinical data and peer-reviewed validation, but pre-revenue status, minimal cash position (~$7.4M as of Q4 2025), and history of stock price volatility and Nasdaq compliance issues present significant execution risk. The company is advancing toward clinical trials but remains highly speculative.
Top Insights
Stock jumped 37% in May 2026 following disclosure of implantable CGM data.
Secured $4M in funding in July 2024 from leading shareholder to support First in Human clinical trial.
Completed $3.0 million public offering in February 2025 at $1.15 per share.
Company faced Nasdaq minimum bid price compliance issues in 2023, with stock falling below $1.00 per share threshold.
Named Competitors
Dexcom G7 — Leading wearable continuous glucose monitoring system
Guardian 4 — Integrated diabetes management with CGM sensors
FreeStyle Libre — Flash glucose monitoring wearable system
Recent Developments
(April 2026) In-vivo ovine study demonstrated sustained performance of CBGM over 240 days, advancing path to FDA IDE submission
(March 2026) CEO Paul V. Goode presented at LSI USA '26 Summit
(January 2026) USPTO issued three patents (US 12,453,494, US 12,458,257, US 12,458,258) for glucose monitoring technology
(February 2025) Completed $3.0 million public offering at $1.15 per share
(July 2024) Secured $4 million funding from shareholder for First in Human clinical trials
Open the full interactive GlucoTrack, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.